St. Jude eyes larger patient group in new renal denervation study

January 30, 2013 by MassDevice staff

Medical device maker St. Jude Medical enrolls the 1st patient in a post-market study of its Enlightn renal denervation system, hoping to expand research to patients with less severe forms of hypertension.

St. Jude Medical's Enlighn renal denervation system

Medtech giant St. Jude Medical (NYSE:STJ) launched a new trial of its Enlightn renal denervation system, hoping to demonstrate the value of the technology in a larger clutch of patients.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Comments

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp